| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 1.969.184 | 2.256.275 | 3.199.324 | 3.721.524 | 3.789.265 | 3.975.955 | 4.841.582 | 6.411.978 | 9.170.729 | 7.892.537 |
| Total Income - EUR | 2.016.143 | 2.284.719 | 3.258.374 | 3.739.535 | 3.823.117 | 4.010.059 | 4.878.833 | 6.433.144 | 9.213.315 | 8.043.848 |
| Total Expenses - EUR | 1.987.521 | 2.254.250 | 3.137.259 | 3.506.019 | 3.602.640 | 3.568.131 | 4.470.247 | 5.942.862 | 8.371.962 | 7.580.615 |
| Gross Profit/Loss - EUR | 28.621 | 30.469 | 121.114 | 233.515 | 220.477 | 441.928 | 408.586 | 490.282 | 841.354 | 463.233 |
| Net Profit/Loss - EUR | 28.621 | 30.469 | 114.000 | 193.391 | 184.733 | 380.141 | 351.108 | 421.500 | 697.917 | 348.289 |
| Employees | 24 | 24 | 0 | 32 | 31 | 31 | 32 | 35 | 36 | 37 |
Check the financial reports for the company - Meditrina Pharmaceuticals S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 19.000 | 21.164 | 25.404 | 23.394 | 21.252 | 28.230 | 32.356 | 37.638 | 35.577 | 37.797 |
| Current Assets | 2.344.298 | 2.312.298 | 2.764.118 | 3.127.563 | 3.499.122 | 4.077.059 | 6.161.626 | 6.909.678 | 7.309.418 | 5.804.938 |
| Inventories | 331.038 | 347.136 | 261.732 | 336.854 | 366.974 | 415.220 | 1.428.639 | 1.805.838 | 1.739.676 | 871.883 |
| Receivables | 1.991.980 | 1.949.230 | 2.438.566 | 2.750.655 | 3.012.094 | 3.623.341 | 4.718.641 | 4.977.393 | 5.560.425 | 4.907.542 |
| Cash | 21.280 | 15.932 | 63.820 | 40.054 | 120.055 | 38.498 | 14.347 | 126.447 | 9.317 | 25.512 |
| Shareholders Funds | 524.704 | 391.217 | 366.005 | 506.736 | 681.656 | 896.110 | 990.929 | 1.089.526 | 1.544.184 | 845.252 |
| Social Capital | 1.217.244 | 1.204.830 | 1.184.738 | 1.162.996 | 1.140.473 | 431.664 | 219.849 | 220.531 | 219.863 | 218.634 |
| Debts | 1.995.672 | 2.140.391 | 2.549.452 | 2.770.513 | 3.025.183 | 3.210.645 | 5.219.932 | 6.008.298 | 5.802.185 | 4.917.745 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Meditrina Pharmaceuticals S.r.l.